Rethinking HLA-B27 Testing: What HLA-B27 Can-and Cannot-Tell Us

Area of Science:

• Immunogenetics
• Rheumatology
• Molecular Biology

Background:

• Human Leukocyte Antigen B27 (HLA-B27) is a well-established genetic risk factor for spondyloarthritis (SpA).
• Despite decades of research since its discovery, the precise mechanisms by which HLA-B27 influences SpA pathogenesis remain incompletely elucidated.
• SpA encompasses a group of inflammatory diseases affecting the axial skeleton and peripheral joints.

Discussion:

• Aberrant antigen presentation by HLA-B27 molecules is a proposed mechanism contributing to SpA.
• Misfolding of HLA-B27 and subsequent endoplasmic reticulum (ER) stress may play a role in disease initiation.
• HLA-B27 is also implicated in modulating innate immune responses, potentially driving inflammation in SpA.

Key Insights:

• HLA-B27's role in SpA is multifaceted, involving antigen presentation, protein misfolding, and immune system dysregulation.
• Understanding these mechanisms is crucial for developing targeted therapies for SpA patients.
• Continued research is essential to fully unravel the complex interplay between HLA-B27 and spondyloarthritis.

Outlook:

• Further investigation into HLA-B27 structure-function relationships may reveal novel therapeutic targets.
• Exploring the precise signaling pathways activated by HLA-B27 misfolding could lead to new treatment strategies.
• Longitudinal studies assessing HLA-B27 dynamics in SpA progression are needed to refine our understanding.